Trevena (TRVN) – Globe Newswire
-
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
-
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
-
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
-
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
-
Trevena Awarded OLINVYK Agreement with Premier, Inc.
-
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
-
Trevena Reports Third Quarter 2023 Results and Provides Business Update
-
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
-
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
-
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
-
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
-
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
-
Trevena Reports Second Quarter 2023 Results and Provides Business Update
-
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
-
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
-
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
-
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
-
Trevena Reports First Quarter 2023 Results and Provides Business Update
-
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
-
Trevena Announces Approval of OLINVYK in China
-
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
-
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
-
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
-
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
-
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
-
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
-
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
-
Trevena Regains Compliance with Nasdaq Listing Requirements
-
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Trevena Announces Reverse Stock Split
-
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
-
Trevena Reports Third Quarter 2022 Results and Provides Business Update
-
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
-
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
-
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
-
Trevena Reports Second Quarter 2022 Results and Provides Business Update
-
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
-
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
-
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
-
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
-
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
-
Trevena to Participate at the JMP Securities Life Sciences Conference
-
Trevena to Present at the H.C. Wainwright Global Investment Conference
-
Trevena Reports First Quarter 2022 Results and Provides Business Update
-
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
-
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
-
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
-
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
-
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
-
Trevena Reports Fourth Quarter and Full Year 2021 Results
Back to TRVN Stock Lookup
